5-HT1A Receptor Function in Normal Subjects on Clinical Doses Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7. -
Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder A
Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder A. Broocks, M.D., Ph.D., B. Bandelow, M.D., Ph.D., K. Koch, U. Bartmann, J. Kinkelbur, M.D., U. Schweiger, M.D., Ph.D., F. Hohagen, M.D., Ph.D., and G. Hajak, M.D., Ph.D. Reduced 5-HT1A-receptor responsiveness has been reported temperature. In comparison to placebo, administration of in patients with panic disorder(PD) and/or agoraphobia ipsapirone was associated with significant increases of (PDA). Although many of these patients are regular various psychological symptoms and plasma cortisol smokers, it has not been examined whether psychological or concentrations. The subgroup of PD patients who were neurobiological effects induced by the selective 5-HT1A- smokers showed significantly higher cortisol responses to receptor agonist, ipsapirone, are affected by the smoking ipsapirone than non-smokers. status of the patients. In conclusion, smoking status has to be taken into In order to clarify this question neuroendocrine account when assessing the responsiveness of 5-HT1A challenges with oral doses of ipsapirone (0.3 mg/kg) and receptors in patients with psychiatric disorders. The placebo were performed in 39 patients with PDA, and prevention of smoking during challenge sessions might not results were compared between patients who smoked (Ͼ10 be the ideal approach in heavy smokers, since sudden cigarettes per day, n ϭ 17) and patients who had been non- abstinence from smoking is likely to affect neurobiological smokers for at least two years (n ϭ 22). and possibly psychological responses to ipsapirone. Patients who were smokers (but did not smoke during [Neuropsychopharmacology 27:270–278, 2002] the challenge procedure) had significantly reduced baseline © 2002 American College of Neuropsychopharmacology. -
Serotonergic Modulation of Suicidal Behaviour: Integrating Preclinical Data with Clinical Practice and Psychotherapy
Serotonergic modulation of suicidal behaviour: integrating preclinical data with clinical practice and psychotherapy Vasileios Boulougouris, Ioannis Malogiannis, George Lockwood, Iannis Zervas & Giuseppe Di Giovanni Experimental Brain Research ISSN 0014-4819 Exp Brain Res DOI 10.1007/s00221-013-3669-z 1 23 Your article is protected by copyright and all rights are held exclusively by Springer- Verlag Berlin Heidelberg. This e-offprint is for personal use only and shall not be self- archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”. 1 23 Author's personal copy Exp Brain Res DOI 10.1007/s00221-013-3669-z SeroTONIN Serotonergic modulation of suicidal behaviour: integrating preclinical data with clinical practice and psychotherapy Vasileios Boulougouris · Ioannis Malogiannis · George Lockwood · Iannis Zervas · Giuseppe Di Giovanni Received: 6 May 2013 / Accepted: 30 July 2013 © Springer-Verlag Berlin Heidelberg 2013 Abstract Many studies have provided important infor- with personality disorders), aiming to invite the reader to mation regarding the anatomy, development and func- integrate some aspects of the neurobiology of human sui- tional organization of the 5-HT system and the alterations cidal behaviour into a model of suicide that can be used in in this system that are present within the brain of the sui- a clinical encounter. -
List of API's Impurities 2019.Pdf
Molecular Molecular Impurity name Chemical Name CAS Number formula weight A ABACAVIR (1R,4S)-Abacavir ; ent-Abacavir ; [(1R,4S)-4-[2-Amino-6- Abacavir EP Impurity A 136470-79-6 C14H18N6O 286.33 (cyclopropylamino)-9H-purin-9-yl]cyclopent-2-enyl]methanol Abacavir USP RC D ; O-Pyrimidine Derivative Abacavir (USP) ; 6- (Cyclopropylamino)-9-[(1R,4S)-4-[[(2,5-diamino-6- chloropyrimidin-4- Abacavir EP Impurity B 1443421-69-9 C18H21ClN10O 428.88 yl)oxy]methyl]cyclopent-2-enyl]-9H-purine-2- amine ; Abacavir USP RC A ; Descyclopropyl Abacavir (USP) ; [(1S,4R)-4- (2,6- Abacavir EP Impurity C 124752-25-6 C11H14N6O 246.27 Diamino-9H-purin-9-yl)cyclopent-2-enyl]methanol. trans-Abacavir Dihydrochloride ; [(1R,4R)-4-[2-Amino-6- Abacavir EP Impurity D (cyclopropylamino)-9H-purin-9-yl]cyclopent-2-enyl]methanol 783292-37-5 C14H20Cl2N6O 359.25 dihydrochloride ; Dihydro Abacavir ; [(1R,3S)-3-[2-Amino-6-(cyclopropylamino)- 9H- Abacavir EP Impurity E 208762-35-0 C14H20N6O 288.35 purin-9-yl]cyclopentyl] methanol. O-t-Butyl Derivative Abacavir (USP) ; Abacavir t-Butyl Ether ; 6- Abacavir EP Impurity F (Cyclopropylamino)-9-[(1R,4S)-4-[[(1,1- 1443421-68-8 C18H26N6O 342.44 dimethylethyl)oxy]methyl]cyclopent-2-enyl]-9H-purine-2- amine. [4-(2,5-Diamino-6-chloropyrimidin-4-ylamino)cyclopent-2- Abacavir USB RC B 141271-12-7 C19H14ClN5O 255.70 enyl]methanol ; Abacavir N6-Cyclopropyl-9H-purine-2,6-diamine. 120503-69-7 C8H10N6 190.21 Cyclopropyl (1R,2R,4S)-2-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)- 4- 3-Hydroxy Abacavir NA C14H20N6O2 304.35 (hydroxymethyl)cyclopentanol Abacavir Enantiomer (1R,4R)-4-[2-Amino-6-(cyclopropyl amino)-9H-purin-9-yl]-2- NA C14H18N6O 286.3 Impurity cyclopentene-1-methanol. -
5-HT1A Receptor Agonist Affects Fear Conditioning Through Stimulations of the Postsynaptic 5-HT1A Receptors in the Title Hippocampus and Amygdala
5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the Title hippocampus and amygdala Author(s) Li, XiaoBai; Inoue, Takeshi; Abekawa, Tomohiro; Weng, ShiMin; Nakagawa, Shin; Izumi, Takeshi; Koyama, Tsukasa European Journal of Pharmacology, 532(1-2), 74-80 Citation https://doi.org/10.1016/j.ejphar.2005.12.008 Issue Date 2006-02-17 Doc URL http://hdl.handle.net/2115/8408 Type article (author version) File Information EJP22907revisedFinal.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP 5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala. XiaoBai Lia, b, Takeshi Inouea, Tomohiro Abekawaa, ShiMin Weng b, Shin Nakagawaa, Takeshi Izumia, Tsukasa Koyamaa a Department of Psychiatry, Neural Function, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan bShanghai Mental Health Center, 600, Wan Ping Nan Lu, Shanghai 200030, China Correspondence to: Takeshi Inoue, MD, PhD, Department of Psychiatry, Neural Function, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan. Tel: +81-11-706-5160; Fax: +81-11-706-5081; E-mail: [email protected] Abstract Evidence from preclinical and clinical studies has shown that 5-HT1A receptor agonists have anxiolytic actions. The anxiolytic actions of 5-HT1A receptor agonists have been tested by our previous studies using fear conditioning. However, little is known about the brain regions of anxiolytic actions of 5-HT1A receptor agonists in this paradigm. In the present study, we investigated the effects of bilateral microinjections of flesinoxan, a selective 5-HT1A receptor agonist, into the hippocampus, amygdala and medial prefrontal cortex on the expression of contextual conditioned freezing and the defecation induced by conditioned fear stress in rats. -
Anxiété, Éthylisme, Motivation Et Performance Cognitive À La Suite D'une Réduction De La Sérotonine Cérébrale Chez L
ANXIÉTÉ, ÉTHYLISME, MOTIVATION ET PERFORMANCE COGNITIVE À LA SUITE D’UNE RÉDUCTION DE LA SÉROTONINE CÉRÉBRALE CHEZ LES SOURIS MUTANTES TPH2 Thèse Francis Lemay Doctorat en psychologie – Recherche et intervention (Orientation clinique) Philosophiæ doctor (Ph.D.) Québec, Canada © Francis Lemay, 2014 Résumé Les troubles affectifs tels que l’anxiété et la dépression majeure sont les troubles psychiatriques les plus diagnostiqués au monde. Parmi leurs causes potentielles figurent le stress chronique et des dysfonctions du système nerveux central, telles que des mutations génétiques. Une mutation de l’enzyme tryptophane hydroxylase 2, responsable de la première étape de la synthèse de la sérotonine cérébrale, a été associée chez l’humain à une forme sévère de dépression majeure à comorbidités multiples. La présente thèse propose d’étudier les effets comportementaux de cette mutation chez la souris. Dans un premier article, deux paradigmes expérimentaux servent à évaluer l’anxiété de souris mutantes (HO) et de souris contrôles (WT) et une tâche d’apprentissage spatial mesure la performance cognitive de ces souris. La réaction anxieuse et les performances cognitives des souris sont également observées suite à un stress chronique récent de contention d’une durée de deux heures par jour, pendant quatre jours consécutifs. Le second article examine la motivation des souris HO à consommer du sucrose ou de la quinine, ainsi que leur préférence pour l’alcool et leur motivation à en consommer. Les expériences effectuées démontrent que les souris HO sont plus anxieuses et présentent des déficits de performance cognitive plus importants que les souris WT. Ces dernières réagissent au stress chronique par des comportements anxieux et des performances cognitives similaires à ceux des souris HO non stressées. -
Clinical Utility of Vilazodone for the Treatment of Adults with Major Depressive Disorder and Theoretical Implications for Future Clinical Use
Neuropsychiatric Disease and Treatment Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use Mandeep Singh Background: Vilazodone is the latest approved antidepressant available in the United States. Thomas L Schwartz Its dual mechanism of action combines the inhibition of serotonin transporters while simultane- ously partially agonizing serotonin-1a (5-HT1A) receptors. This combined activity results in SUNY Upstate Medical University, Psychiatry Department, Syracuse, serotonin facilitation across the brain’s serotonergic pathways, which has been termed by the NY, USA authors as that of a serotonin partial agonist and reuptake inhibitor, or SPARI. Objective: The authors to review laboratory, animal model data, and human trial data to synthesize a working theory regarding the mechanism of antidepressant action of this agent and regarding its potential for additional indications. Methods: A MEDLINE and Internet search was conducted and the resultant evidence For personal use only. reviewed. Results: Vilazodone has randomized, controlled empirical data which has garnered it an approval for treating major depressive disorder. It combines two well-known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants are published, the efficacy data for vilazodone appears comparable to other known antidepressants, with associated gastrointestinal side effects similar to serotonin selective reuptake inhibitor and serotonin norepinephrine reuptake inhibitor antidepressants, but potentially with a lower incidence of sexual side effects and weight gain. Discussion: As a new option for the treatment of major depressive disorder, vilazodone, due to its unique SPARI mechanism of action, may hold promise for patients who cannot tolerate or have not responded to previous antidepressant monotherapies. -
A Brief Summary for 5-HT Receptors
ndrom Sy es tic & e G n e e n G e f T o Watry and Lu, J Genet Syndr Gene Ther 2013, 4:2 Journal of Genetic Syndromes h l e a r n a r p DOI: 10.4172/2157-7412.1000129 u y o J & Gene Therapy ISSN: 2157-7412 Short Commentary Open Access A Brief Summary for 5-HT Receptors Watry S and Lu J* Department of Neuroscience and Department of Neurology, School of Medicine and Public Health, Waisman Center, University of Wisconsin, Madison, WI 53705, USA As a group of G protein-coupled receptors (GPCRs) and ligand- (Anpirtoline) [42]; CGS 12066B [43]; SB 216641 [44]; RU 24969 [45]; gated ion channels (LGICs), the serotonin (5-HT) receptors are CP 93129 [46]. found in the central and peripheral nervous systems. After activated Application value: Depression [47]; Anxiety [48]; Aggression by the neurotransmitter serotonin, their natural ligand, 5-HT [49]; Migraine [50]; Drug Addicton [51]; increased locomotor activity receptors mediate both excitatory and inhibitory neurotransmission [52]; brain reward mechanisms (agonist); Alcoholism [53]; Sleep [54]; by modulating the release of many neurotransmitters, including hypothermia [55]. glutamate, GABA, dopamine, epinephrine/norepinephrine, and acetylcholine, as well as many hormones, including oxytocin, prolactin, Receptor: 5-HT 1D [56] vasopressin, cortisol, corticotropin, and substance P, among others. 5-HT receptors influence various biological and neurological processes Structure: GPCR [56]. such as aggression, anxiety, appetite, cognition, learning, memory, Localization: Raphe nuclei; Cortex, Caudate, Globus Pallidus mood, nausea, sleep, and thermoregulation. Accordingly, 5-HT [57]; Basal Ganglia, Substantia Nigra, Hippocampal Formation, receptors are the target of a variety of pharmaceutical drugs, including Raphe Nuclei [58]; Caudate Nucleus, Lateral Geniculate Nuclei, Spinal many antidepressants, antipsychotics, anorectics, antiemetics, Trigominal Nucleus [32]; Globus Pallidus [59]. -
Centre for Reviews and Dissemination
Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications Casacalenda N, Boulenger J P Authors' objectives To assess the efficacy of anxiolytics (alprazolam and azapirones) in major depressive disorder (MDD) and of antidepressants in generalized anxiety disorder (GAD), thereby exploiting the possible theoretical and clinical implications of this efficacy. Searching MEDLINE was searched from January 1980 to September 1997 for English language peer-reviewed articles using the following keywords: depressive disorders, anxiety disorders, generalized anxiety disorder, antidepressants, antianxiety agents, benzodiazepines and buspirone. Bibliographies of identified studies were examined. Study selection Study designs of evaluations included in the review Randomised, double-blind trials (RCT) with a sample size of 30 patients or more that compared anxiolytics and antidepressants in the acute treatment of GAD or MDD were included. Specific interventions included in the review The following therapies were studied: benzodiazepines including alprazolam, diazepam, and lorazepam; tricyclic antidepressants (TCA) including desipramine, amitryptilline, imipramine, and doxepin); azapirones (including buspirone, ipsapirone, and gepirone); and placebo. Duration of treatment ranged from 4 to 8 weeks. Participants included in the review Adult patients with generalised anxiety disorder (GAD) or major depressive disorder (MDD) who were not being simultaneously treated with psychotherapy -
Blunted Temperature and Cortisol Responses to Ipsapirone in Major Depression: Lack of Enhancement by Electroconvulsive Therapy Baruch Shapira, Michael E
Psychoneuroendocrinology 25 (2000) 421–438 www.elsevier.com/locate/psyneuen Blunted temperature and cortisol responses to ipsapirone in major depression: lack of enhancement by electroconvulsive therapy Baruch Shapira, Michael E. Newman, Yevgenia Gelfin, Bernard Lerer * Biological Psychiatry Unit, Hadassah-Hebrew University Medical Center, Ein Karem, Jerusalem, 91120, Israel Received 5 July 1999; accepted 24 September 1999 Abstract Depression has been shown in some studies to be associated with a reduction in hypothal- amic 5-HT1A receptor function, as indicated by reduced hormone and/or hypothermic responses to 5-HT1A agonists such as ipsapirone. The hypothermic response to ipsapirone was reduced in depressed patients treated with amitriptyline. Hormone and hypothermic responses to 5- HT1A agonists were reduced in normal subjects administered specific serotonin reuptake inhibi- tors. Effects of electroconvulsive therapy (ECT) on 5-HT1A receptor-mediated responses in humans have not been reported. In the present work, ten depressed patients and 15 control subjects were challenged with placebo and with 0.3 mg/kg ipsapirone, administered 48 h apart in a randomised double blind design. Hypothermic, growth hormone (GH) and cortisol responses were measured. Seven of the depressed patients were treated with a course of ECT, and placebo and ipsapirone challenges were repeated 24 and 72 h after the last treatment. The cortisol response to ipsapirone was significantly reduced in the depressed patients compared with controls. The hypothermic response to ipsapirone was totally abolished in the depressed patients. When tested after a course of ECT, the seven depressed patients again showed reduced or blunted responses. We conclude that hypothalamic 5-HT1A receptor function is reduced in depression. -
Clinical Utility of Vilazodone for the Treatment of Adults with Major Depressive Disorder and Theoretical Implications for Future Clinical Use
Neuropsychiatric Disease and Treatment Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use Mandeep Singh Background: Vilazodone is the latest approved antidepressant available in the United States. Thomas L Schwartz Its dual mechanism of action combines the inhibition of serotonin transporters while simultane- ously partially agonizing serotonin-1a (5-HT1A) receptors. This combined activity results in SUNY Upstate Medical University, Psychiatry Department, Syracuse, serotonin facilitation across the brain’s serotonergic pathways, which has been termed by the NY, USA authors as that of a serotonin partial agonist and reuptake inhibitor, or SPARI. Objective: The authors to review laboratory, animal model data, and human trial data to synthesize a working theory regarding the mechanism of antidepressant action of this agent and regarding its potential for additional indications. Methods: A MEDLINE and Internet search was conducted and the resultant evidence reviewed. Results: Vilazodone has randomized, controlled empirical data which has garnered it an approval for treating major depressive disorder. It combines two well-known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants are published, the efficacy data for vilazodone appears comparable to other known antidepressants, with associated gastrointestinal side effects similar to serotonin selective reuptake inhibitor and serotonin norepinephrine reuptake inhibitor antidepressants, but potentially with a lower incidence of sexual side effects and weight gain. Discussion: As a new option for the treatment of major depressive disorder, vilazodone, due to its unique SPARI mechanism of action, may hold promise for patients who cannot tolerate or have not responded to previous antidepressant monotherapies. -
Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists As New Therapeutic Agents Adeline Etievant#, Cécile Bétry#, and Nasser Haddjeri*,1
The Open Neuropsychopharmacology Journal, 2010, 3, 1-12 1 Open Access Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents Adeline Etievant#, Cécile Bétry#, and Nasser Haddjeri*,1 Laboratory of Neuropharmacology, Faculty of Pharmacy, University Lyon I, EAC CNRS 5006, 8 Avenue Rockefeller 69373 LYON Cedex 08 France Abstract: The therapeutic efficacy of current antipsychotic or antidepressant agents still present important drawbacks such as delayed onset of action and a high percentage of non-responders. Despite significant advancements in the devel- opment of new drugs with more acceptable side-effect profiles, patients with schizophrenia or major depression experi- ence substantial disability and burden of disease. The present review discusses the usefulness of partial dopamine D2/serotonin 5-HT1A receptors agonists in the treatment of schizophrenia, major depression and bipolar disorder as well as in Parkinson’s disease. Partial agonists can behave as modulators since their intrinsic activity or efficacy of a partial ago- nist depends on the target receptor population and the local concentrations of the natural neurotransmitter. Thus, these drugs may restore adequate neurotransmission while inducing less side effects. In schizophrenia, partial DA D2/5-HT1A receptor agonists (like aripiprazole or bifeprunox), by stabilizing DA system via a preferential reduction of phasic DA re- lease, reduce side effects i.e. extrapyramidal symptoms and improve cognition by acting on 5-HT1A receptors. Aripipra- zole appears also as a promising agent for the treatment of depression since it potentiates the effect of SSRIs in resistant treatment depression. Concerning bipolar disorders aripiprazole may have only a benefit effect in the treatment of manic episodes.